A Preview Of Unifi’s Earnings

Unifi (NYSE:UFI) is set to give its latest quarterly earnings report on Wednesday, 2024-01-31. Here’s what investors need…

Unifi (NYSE:UFI) is set to give its latest quarterly earnings report on Wednesday, 2024-01-31. Here’s what investors need to know before the announcement.

Analysts estimate that Unifi will report an earnings per share (EPS) of $-0.85.

Unifi bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company missed EPS by $0.26, which was followed by a 8.09% drop in the share price the next day.

Here’s a look at Unifi’s past performance and the resulting price change:

Quarter Q1 2024 Q4 2023 Q3 2023 Q2 2023
EPS Estimate -0.47 -0.29 -0.30 -1.28
EPS Actual -0.73 -0.39 -0.25 -1.21
Price Change % -8.09% -16.97% -8.05% 12.24%

eps graph

Stock Performance

Shares of Unifi were trading at $6.56 as of January 29. Over the last 52-week period, shares are down 27.32%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

To track all earnings releases for Unifi visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Cannabinoid-Based Products Maker Sees Triple-Digit Growth In 2023 Gross Profit, Revenue Surges 314% YoY

Cannabinoids-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) reported on Tuesday year-end 2023 results and audited financial statements. The Canadian company reported CA$16.8 million ($12.3 million) in total revenue, up by 314% year-over-year. Avicanna mostly attributed a surge in revenue to the acquisition of Medical Cannabis by Shoppers from Shoppers Drug Mart and the launch of MyMedi.ca. "2023 was a tremendous year for Avicanna where we solidified our leadership position in the Canadian medical cannabis sector through our proprietary products and the launch of MyMedi.ca," he said. "We have successfully demonstrated the scalability of our revenues and made significant improvements in our fundamentals while advancing all our business pillars."

AVCNF